Activity of Eribulin in a primary culture of well-differentiated/dedifferentiated adipocytic sarcoma

22Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

Eribulin mesylate is a novel, non-taxane, synthetic microtubule inhibitor showing antitumor activity in a wide range of tumors including soft tissue sarcomas (STS). Eribulin has been recently approved for the treatment of metastatic liposarcoma (LPS) patients previously treated with anthracyclines. This work investigated the mechanism of action of this innovative antitubulin agent in well-differentiated/dedifferentiated LPS (ALT/DDLPS) which represents one of the most common adipocytic sarcoma histotypes. A primary culture of ALT/DDLPS from a 54-year-old patient was established. The anticancer activity of eribulin on the patient-derived primary culture was assessed by MTT and tunel assays. Eribulin efficacy was compared to other drugs approved for the treatment of STS. Cell migration and morphology were examined after exposure to eribulin to better understand the drug mechanism of action. Finally, Western blot analysis of apoptosis and migration proteins was performed. The results showed that eribulin exerts its antiproliferative effect by the arrest of cell motility and induction of apoptosis. Our results highlighted the activity of eribulin in the treatment of ALT/DDLPS patients.

Cite

CITATION STYLE

APA

De Vita, A., Miserocchi, G., Recine, F., Mercatali, L., Pieri, F., Medri, L., … Ibrahim, T. (2016). Activity of Eribulin in a primary culture of well-differentiated/dedifferentiated adipocytic sarcoma. Molecules, 21(12). https://doi.org/10.3390/molecules21121662

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free